Lawrence C, Roberts C, Galides C, Chamberlain S, Hou R
J Psychopharmacol. 2024; 39(2):132-140.
PMID: 39655766
PMC: 11831860.
DOI: 10.1177/02698811241303652.
Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X
Int J Mol Sci. 2024; 25(19).
PMID: 39408997
PMC: 11477438.
DOI: 10.3390/ijms251910668.
Arizanovska D, Emodogo J, Lally A, Palavicino-Maggio C, Liebl D, Folorunso O
Amino Acids. 2023; 55(11):1501-1517.
PMID: 37833512
PMC: 10689556.
DOI: 10.1007/s00726-023-03338-6.
Gannon L, Reynolds J, Mahon M, Gaughran F, Lally J
Ther Adv Psychopharmacol. 2023; 13:20451253231168788.
PMID: 37187727
PMC: 10176543.
DOI: 10.1177/20451253231168788.
Nasyrova R, Khasanova A, Altynbekov K, Asadullin A, Markina E, Gayduk A
Nutrients. 2022; 14(23).
PMID: 36501171
PMC: 9736950.
DOI: 10.3390/nu14235142.
Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research.
Kuo C, Lin C, Lane H
CNS Drugs. 2022; 36(11):1143-1153.
PMID: 36194364
DOI: 10.1007/s40263-022-00959-5.
Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia.
Pei J, Luo D, Gau S, Chang C, Lai W
Front Psychiatry. 2021; 12:742058.
PMID: 34658976
PMC: 8517243.
DOI: 10.3389/fpsyt.2021.742058.
D-Serine: A Cross Species Review of Safety.
Meftah A, Hasegawa H, Kantrowitz J
Front Psychiatry. 2021; 12:726365.
PMID: 34447324
PMC: 8384137.
DOI: 10.3389/fpsyt.2021.726365.
Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia.
Wu Q, Huang J, Wu R
Front Neurosci. 2021; 15:641047.
PMID: 33912003
PMC: 8072017.
DOI: 10.3389/fnins.2021.641047.
Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia .
de la Garrigue N, Glasser J, Sehatpour P, Iosifescu D, Dias E, Carlson M
J Psychiatr Brain Sci. 2020; 5(4).
PMID: 32856005
PMC: 7448686.
An Ensemble Approach to Predict Schizophrenia Using Protein Data in the N-methyl-D-Aspartate Receptor (NMDAR) and Tryptophan Catabolic Pathways.
Lin E, Lin C, Hung C, Lane H
Front Bioeng Biotechnol. 2020; 8:569.
PMID: 32582679
PMC: 7287032.
DOI: 10.3389/fbioe.2020.00569.
D-Serine: Potential Therapeutic Agent and/or Biomarker in Schizophrenia and Depression?.
MacKay M, Kravtsenyuk M, Thomas R, Mitchell N, Dursun S, Baker G
Front Psychiatry. 2019; 10:25.
PMID: 30787885
PMC: 6372501.
DOI: 10.3389/fpsyt.2019.00025.
Combination of Genetic Variation and G72 Protein Level to Detect Schizophrenia: Machine Learning Approaches.
Lin E, Lin C, Lai Y, Huang C, Huang Y, Lane H
Front Psychiatry. 2018; 9:566.
PMID: 30459659
PMC: 6232512.
DOI: 10.3389/fpsyt.2018.00566.
Natural Medicines for Psychotic Disorders: A Systematic Review.
Hoenders H, Bartels-Velthuis A, Vollbehr N, Bruggeman R, Knegtering H, de Jong J
J Nerv Ment Dis. 2018; 206(2):81-101.
PMID: 29373456
PMC: 5794244.
DOI: 10.1097/NMD.0000000000000782.
Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation.
Fujita Y, Ishima T, Hashimoto K
Sci Rep. 2016; 6:37261.
PMID: 27853241
PMC: 5112512.
DOI: 10.1038/srep37261.
In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: application to schizophrenia.
Wijtenburg S, Yang S, Fischer B, Rowland L
Neurosci Biobehav Rev. 2015; 51:276-95.
PMID: 25614132
PMC: 4427237.
DOI: 10.1016/j.neubiorev.2015.01.007.
